6′-Methoxy Raloxifene-analog enhances mouse bone properties with reduced estrogen receptor binding

Raloxifene (RAL) is an FDA-approved drug used to treat osteoporosis in postmenopausal women. RAL suppresses bone loss primarily through its role as a selective estrogen receptor modulator (SERM). This hormonal estrogen therapy promotes unintended side effects, such as hot flashes and increased throm...

Descripción completa

Detalles Bibliográficos
Autores principales: Powell, Katherine M., Brown, Alexa P., Skaggs, Cayla G., Pulliam, Alexis N., Berman, Alycia G., Deosthale, Padmini, Plotkin, Lilian I., Allen, Matthew R., Williams, David R., Wallace, Joseph M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992940/
https://www.ncbi.nlm.nih.gov/pubmed/32016137
http://dx.doi.org/10.1016/j.bonr.2020.100246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992940/
https://www.ncbi.nlm.nih.gov/pubmed/32016137
http://dx.doi.org/10.1016/j.bonr.2020.100246

Ejemplares similares